Fairtility

Company Overview

Snapshot

Founded in December 2019 by Eran Eshed and Dr. Assaf Ben-Meir, Fairtility operates with 11–50 employees. The company has raised $18.5M across 3 funding rounds from 3 investors.

Business overview

Fairtility is a Health Tech & Life Sciences company that powers in vitro fertilization (IVF) through transparent artificial intelligence to improve outcomes. Its core product, CHLOE (Cultivating Human Life through Optimal Embryos), is an AI-based decision support tool that provides clinicians with visibility into clinical and laboratory parameters to enhance IVF success. The company serves the digital healthcare market, aiming to reduce the number of IVF cycles needed for live birth, minimize burdens on prospective parents, and facilitate collaborative discussions between clinicians and patients.

Strategic signal

In April 2022, Fairtility's AI-trained embryo labeling technique was highlighted for boosting IVF success rates. This signals a significant advancement in fertility treatment, demonstrating the company's capability to leverage artificial intelligence for tangible improvements in clinical outcomes and potentially validating its technology for broader adoption in the reproductive health market.

Company Intelligence Q&A

What is Fairtility's primary focus?

Fairtility focuses on powering in vitro fertilization (IVF) through transparent artificial intelligence to improve outcomes for prospective parents and clinicians.

When was Fairtility founded and by whom?

Fairtility was founded in December 2019 by Eran Eshed and Dr. Assaf Ben-Meir.

What is CHLOE?

CHLOE (Cultivating Human Life through Optimal Embryos) is Fairtility's transparent AI-based decision support tool that provides clinicians with complete visibility into clinical and laboratory parameters to help improve IVF outcomes.

What was a significant development regarding Fairtility's technology?

In April 2022, an AI-trained embryo labeling technique developed by Fairtility was noted for boosting IVF success rates.